Business
Collaborative Services Agreement
Collaborative Services Agreement.
About this update from Valirx Plc
[{"type":"text","content":"\n\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nCollaborative Services Agreement\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that the CompanyÕs wholly owned subsidiary, Inaphaea BioLabs Limited (\"Inaphaea\"), has entered into a collaborative services agreement with Agility Life Sciences Limited (\"Agility\") (\"Collaborative Services Agreement\").\nThe Collaborative Services Agreement recognises the synergy between Inaphaea's growing capabilities as a translational contract research organisation (tCRO®) and Agility's capabilities for formulation development and optimisation, pre-formulation studies and analysis.\nUnder the agreement, service users of Inaphaea will be able to benefit from Agility's capabilities in a single service contract with Inaphaea and similarly, service users of Agility will be able to access Inaphaea's capabilities through their service contract with Agility. This will enable a coherent, single point of contact for service users to formulate and test their drug candidates.\nDr Suzy Dilly, CEO at ValiRx explains \"We have appreciated the skills and creativity displayed by Agility during the two projects we have run with them, so we're delighted to be able to offer these capabilities to our service users, as well as to continue using these capabilities for our in-house programmes.\n\"In a comparative manner to our collaborative services agreement with Physiomics announced in April 2023, this new arrangement with Agility further expands the Inaphaea service capability. This agreement is very much reciprocal, and we expect to be able to offer our services to Agility customers just as much as offering their services to ours.\"\nProfessor Claire Thompson, CEO at Agility commented \"We are really excited about entering into this Collaborative Service Agreement with Inaphaea. This will enable our clients to take the next steps in their development programmes by testing their prototype formulations in the Inaphaea cell based studies. We believe this will be beneficial to both companies as well as to our clients, creating a more comprehensive scientific environment, and accelerating development timelines.\"\nThe Directors of the Company take responsibility for this announcement.\nFor more informati...